Galina V. Shchelkova
Research Subjects
Galina V. Shchelkova has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Irina Evgenievna Chazova
E.I. Chazov National Medical Research Center Of Cardiology
8 shared publications - Nikolay M. Danilov
E.I. Chazov National Medical Research Center Of Cardiology
5 shared publications - Sergey Yu. Yarovoy
Chazov National Medical Research Center of Cardiology
5 shared publications - Ekaterina O. Dinevich
Chazov National Medical Research Center of Cardiology
4 shared publications - Oksana Kislyak
Pirogov Russian National Research Medical University
3 shared publications - Aleksander Yu. Litvin
E.I. Chazov National Medical Research Center Of Cardiology; Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- Open Access
- 22 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (1) , 4541
Transient ST-segment elevation in endovascular patent foramen ovale closure: a case report
Introduction . The complication rate of endovascular patent foramen ovale (PFO) closure is considered low. However, for most of complications, the rate has not been precisely determined. The most serious intraoperative complications include damage to the heart wall and vessels with bleeding, malpositioned occlude device, thromboembolism, and air embolism. Reports of severe and potentially fatal complications are rare, making their consideration and the determination of treatment strategies crucial. Brief description . Patient K. aged 36 years had an ischemic stroke. Examination revealed a PFO with significant bypass grafting. Endovascular closure of the PFO was recommended to prevent recurrent ischemic events. During surgery, ST segment elevation was recorded in leads II and III. Selective coronary angiography revealed no contrast enhancement in the distal posterolateral and posterior descending arteries. Intracoronary nitroglycerin was administered, which restored flow in the artery. After the patient's condition stabilized, endovascular closure of the PFO was successfully completed, and an occluder was implanted. Discussion . Possible causes of intraoperative ST segment elevation include gas embolism from air bubbles remaining in the delivery system after flushing, and mechanical irritation of the interatrial septum. Preventive measures include thorough flushing of the delivery system and selection of the occluder size based on heart anatomy.
- 22 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (1) , 4541
Open AccessTransient ST-segment elevation in endovascular patent foramen ovale closure: a case report
Introduction . The complication rate of endovascular patent foramen ovale (PFO) closure is considered low. However, for most of complications, the rate has not been precisely determined. The most serious intraoperative complications include damage to the heart wall and vessels with bleeding, malpositioned occlude device, thromboembolism, and air embolism. Reports of severe and potentially fatal complications are rare, making their consideration and the determination of treatment strategies crucial. Brief description . Patient K. aged 36 years had an ischemic stroke. Examination revealed a PFO with significant bypass grafting. Endovascular closure of the PFO was recommended to prevent recurrent ischemic events. During surgery, ST segment elevation was recorded in leads II and III. Selective coronary angiography revealed no contrast enhancement in the distal posterolateral and posterior descending arteries. Intracoronary nitroglycerin was administered, which restored flow in the artery. After the patient's condition stabilized, endovascular closure of the PFO was successfully completed, and an occluder was implanted. Discussion . Possible causes of intraoperative ST segment elevation include gas embolism from air bubbles remaining in the delivery system after flushing, and mechanical irritation of the interatrial septum. Preventive measures include thorough flushing of the delivery system and selection of the occluder size based on heart anatomy.
- 30 December 2025
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 20 (4) , 101-111
Assessment of adherence to treatment in patients with resistant arterial hypertension according to Russian-language literature. A systematic review
Objective. To study the possibility of assessing the adherence to therapy in patients with resistant hypertension (RH) according to Russian-language literature. Material and methods. RH was defined according to clinical guidelines of the Russian Medical Society on Arterial Hypertension (2021). Data were searched in electronic databases and searching engines Google Scholar, eLIBRARY.RU, Central Scientific Medical Library (database inception to 01.12.2023). According to inclusion and exclusion criteria, two independent researchers extracted the articles. Disagreements between researchers were resolved by the third researcher. Study quality was assessed using the Newcastle-Ottawa scale. Results. Among 1610 primary identified publications, 1473 studies were screened. Finally, the authors assessed 49 full-text articles for eligibility. Four studies were selected for qualitative analysis. There were 256 patients. Adherence was assessed using the Morisky—Green questionnaire in original or modified versions. Analysis revealed significant heterogeneity in results. Discussion. Objective assessment of adherence to treatment in this disease and development of measures for its improvement are associated with certain difficulties that limits the number of available studies. The authors performed a systematic review and assessed the possibility of structuring and analyzing the information presented in modern Russian-language literature. Conclusion. Most results indicate low adherence among patients that suggests lower real prevalence of RH, as well as reduced effectiveness of treatment due to non-compliance with drug regimen.
- 30 December 2025
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 20 (4) , 101-111
Assessment of adherence to treatment in patients with resistant arterial hypertension according to Russian-language literature. A systematic review
Objective. To study the possibility of assessing the adherence to therapy in patients with resistant hypertension (RH) according to Russian-language literature. Material and methods. RH was defined according to clinical guidelines of the Russian Medical Society on Arterial Hypertension (2021). Data were searched in electronic databases and searching engines Google Scholar, eLIBRARY.RU, Central Scientific Medical Library (database inception to 01.12.2023). According to inclusion and exclusion criteria, two independent researchers extracted the articles. Disagreements between researchers were resolved by the third researcher. Study quality was assessed using the Newcastle-Ottawa scale. Results. Among 1610 primary identified publications, 1473 studies were screened. Finally, the authors assessed 49 full-text articles for eligibility. Four studies were selected for qualitative analysis. There were 256 patients. Adherence was assessed using the Morisky—Green questionnaire in original or modified versions. Analysis revealed significant heterogeneity in results. Discussion. Objective assessment of adherence to treatment in this disease and development of measures for its improvement are associated with certain difficulties that limits the number of available studies. The authors performed a systematic review and assessed the possibility of structuring and analyzing the information presented in modern Russian-language literature. Conclusion. Most results indicate low adherence among patients that suggests lower real prevalence of RH, as well as reduced effectiveness of treatment due to non-compliance with drug regimen.
- Open Access
- 20 October 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (9) , 793-799
Vaccination pneumococcal infection and cardiovascular diseases: a review
Cardiopulmonary comorbidity is a serious health threat at any age. Community-acquired pneumonia caused by Streptococcus pneumoniae has a proven negative effect in terms of the incidence of new and decompensation of known cardiovascular pathologies, such as myocardial infarction, cerebrovascular accident, heart failure. An additional incentive for the widespread use of pneumococcal vaccination is the good availability of the vaccine and the simple immunization schedule. However, current recommendations have significant differences of opinion regarding target groups for vaccination both among themselves and with the existing evidence base. Low prevalence of pneumococcal vaccination does not allow for the full use of even the well-known advantages of this method in reducing cardiovascular risk. The proposed review discusses possible mechanisms of the impact of pneumococcal infection on the human body, cardioprotective effects of vaccination, modern studies on the possibilities of vaccination among people with cardiovascular diseases; the effect of vaccination on the frequency of cardiovascular events and mortality is considered. The place of pneumococcal infection prevention in current clinical guidelines and its effect on patients' prognosis are indicated. The authors argue for the need for further research in order to obtain sufficient data on the protective effect of vaccination for specific cardiovascular diseases and target patient groups.
- 20 October 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (9) , 793-799
Open AccessVaccination pneumococcal infection and cardiovascular diseases: a review
Cardiopulmonary comorbidity is a serious health threat at any age. Community-acquired pneumonia caused by Streptococcus pneumoniae has a proven negative effect in terms of the incidence of new and decompensation of known cardiovascular pathologies, such as myocardial infarction, cerebrovascular accident, heart failure. An additional incentive for the widespread use of pneumococcal vaccination is the good availability of the vaccine and the simple immunization schedule. However, current recommendations have significant differences of opinion regarding target groups for vaccination both among themselves and with the existing evidence base. Low prevalence of pneumococcal vaccination does not allow for the full use of even the well-known advantages of this method in reducing cardiovascular risk. The proposed review discusses possible mechanisms of the impact of pneumococcal infection on the human body, cardioprotective effects of vaccination, modern studies on the possibilities of vaccination among people with cardiovascular diseases; the effect of vaccination on the frequency of cardiovascular events and mortality is considered. The place of pneumococcal infection prevention in current clinical guidelines and its effect on patients' prognosis are indicated. The authors argue for the need for further research in order to obtain sufficient data on the protective effect of vaccination for specific cardiovascular diseases and target patient groups.
- Open Access
- 25 December 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (4) , 5-110
Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.
- 25 December 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (4) , 5-110
Open AccessClinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.
- Open Access
- 10 October 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (9) , 879-884
Metabolic disorders in patients with chronic thromboembolic pulmonary hypertension
Aim. To analyze the relationship between metabolic disorders and obesity with hemodynamic parameters and the severity of the condition of patients with chronic thromboembolic pulmonary hypertension (CTEPH) based on the POLET register. Materials and methods. The study included patients with CTEPH from the POLET register. Data from medical history, lipid profile, glycemia, uric acid level, weight, height, functional class (FC), distance in the 6-minute walk test (6MWT), echocardiography, and right heart catheterization were used for analysis. Results. The study included 84 patients 60±14 years old, including 45 men. The majority of patients had FC III – 51 (65%), which corresponded to 6MWT – 338±113 m. Nineteen (23%) people had experience in taking PAH specific therapy, 37 (46%) had cardiovascular comorbidity. In the general group, the body mass index (BMI) was 25.7±4.5 kg/m2, and normal glycemia, lipid profile, and uric acid levels were also determined. mPAP was 51±12 mmHg, RA area was 25.5 (20; 30) cm2. Correlations were identified between: RA area and the level of total cholesterol (r=0.60; p0.01), triglycerides (r=-0.24; p0.001), LDL cholesterol (r=0.75; p=0.04), uric acid (r=0.75; p=0.03); total cholesterol and 6MWT (r=0.44; p=0.04). Analysis of metabolic disorders, FC and comorbidity revealed differences between FC III and IV groups in the level of HDL cholesterol (p=0.02) and triglycerides (p0.01). Conclusion. The POLET registry includes mainly older patients. Severe FC (87% – III and IV) may be a result of the older age and the presence of concomitant pathology in almost half of the patients. The discovered relationships between the area of RA and FC with lipid and purine metabolism were discovered for the first time, however, they correspond to the direction of the world scientific researches, are important due to the use of these indicators in the scale for calculating the risk of death in patients with PAH and require further development.
- 10 October 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (9) , 879-884
Open AccessMetabolic disorders in patients with chronic thromboembolic pulmonary hypertension
Aim. To analyze the relationship between metabolic disorders and obesity with hemodynamic parameters and the severity of the condition of patients with chronic thromboembolic pulmonary hypertension (CTEPH) based on the POLET register. Materials and methods. The study included patients with CTEPH from the POLET register. Data from medical history, lipid profile, glycemia, uric acid level, weight, height, functional class (FC), distance in the 6-minute walk test (6MWT), echocardiography, and right heart catheterization were used for analysis. Results. The study included 84 patients 60±14 years old, including 45 men. The majority of patients had FC III – 51 (65%), which corresponded to 6MWT – 338±113 m. Nineteen (23%) people had experience in taking PAH specific therapy, 37 (46%) had cardiovascular comorbidity. In the general group, the body mass index (BMI) was 25.7±4.5 kg/m2, and normal glycemia, lipid profile, and uric acid levels were also determined. mPAP was 51±12 mmHg, RA area was 25.5 (20; 30) cm2. Correlations were identified between: RA area and the level of total cholesterol (r=0.60; p0.01), triglycerides (r=-0.24; p0.001), LDL cholesterol (r=0.75; p=0.04), uric acid (r=0.75; p=0.03); total cholesterol and 6MWT (r=0.44; p=0.04). Analysis of metabolic disorders, FC and comorbidity revealed differences between FC III and IV groups in the level of HDL cholesterol (p=0.02) and triglycerides (p0.01). Conclusion. The POLET registry includes mainly older patients. Severe FC (87% – III and IV) may be a result of the older age and the presence of concomitant pathology in almost half of the patients. The discovered relationships between the area of RA and FC with lipid and purine metabolism were discovered for the first time, however, they correspond to the direction of the world scientific researches, are important due to the use of these indicators in the scale for calculating the risk of death in patients with PAH and require further development.
- Open Access
- 25 March 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (1) , 37-46
Pulmonary hypertension and metabolic disorders
This review presents current data regarding the relationship between hyperuricemia, obesity, diabetes mellitus, lipid disorders and pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH). Hyperuricemia is associated with a higher risk of developing of PAH, worse prognosis of PAH and greater severity of the patient's condition. Obesity leads to the development of pro-inflammatory and vasoconstrictor effects, hypoxia, which contributes to the progression of PH, however, the survival rate of patients with PH and overweight or obesity is higher than with normal or reduced body weight. Diabetes mellitus and concomitant insulin resistance are associated with a high risk of hospitalization for right ventricular heart failure and mortality. The presence of PAH is associated with lower values of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and probably high-density lipoprotein cholesterol (HDL-C). At the same time, higher levels of LDL-С and HDL-С in PAH and CTEPH determine a better prognosis of the disease.All metabolic disorders considered have common mechanisms of influence on PH. Further study of their pathogenetic basis will make it possible to develop unified approaches to methods of their correction in patients with various types of pulmonary hypertension.
- 25 March 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (1) , 37-46
Open AccessPulmonary hypertension and metabolic disorders
This review presents current data regarding the relationship between hyperuricemia, obesity, diabetes mellitus, lipid disorders and pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH). Hyperuricemia is associated with a higher risk of developing of PAH, worse prognosis of PAH and greater severity of the patient's condition. Obesity leads to the development of pro-inflammatory and vasoconstrictor effects, hypoxia, which contributes to the progression of PH, however, the survival rate of patients with PH and overweight or obesity is higher than with normal or reduced body weight. Diabetes mellitus and concomitant insulin resistance are associated with a high risk of hospitalization for right ventricular heart failure and mortality. The presence of PAH is associated with lower values of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and probably high-density lipoprotein cholesterol (HDL-C). At the same time, higher levels of LDL-С and HDL-С in PAH and CTEPH determine a better prognosis of the disease.All metabolic disorders considered have common mechanisms of influence on PH. Further study of their pathogenetic basis will make it possible to develop unified approaches to methods of their correction in patients with various types of pulmonary hypertension.
- Open Access
- 26 June 2023
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 20 (2) , 5-20
Consensus on renovascular hypertension: diagnosis and treatment
The clinical significance of renovascular arterial hypertension is determined by it is high prevalence as well as it is negative impact on prognosis. The most common causes of renovascular arterial hypertension are atherosclerotic stenosis of the renal arteries and fibromuscular dysplasia. Renovascular arterial hypertension is characterized by the development of blood pressure resistant to antihypertensive therapy with an unfavorable prognosis of worsening renal function and cardiovascular complications. Currently, the most available screening method in the diagnosis of renovascular arterial hypertension is duplex scanning of the renal arteries. Non-invasive diagnostic methods also include magnetic resonance and multispiral computed tomography with intravenous contrast. Contrast angiography remains “the golden standard” for diagnosing renovascular arterial hypertension and determining the indications for surgical treatment. Together with the use of diagnostic techniques such as measurement of translesion pressure gradient and fractional blood flow reserve, it allows to assess the functional significance of renal artery stenosis. Treatment of renovascular arterial hypertension is a complex process aimed at normalization of blood pressure, improvement of renal function, as well as mortality and cardiovascular risk reduction. To date, the feasibility of endovascular treatment remains an open question. More often the preference is given to conservative treatment. The indications for renal artery revascularization are less obvious, available clinical guidelines and results of large trials are controversial.
- 26 June 2023
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 20 (2) , 5-20
Open AccessConsensus on renovascular hypertension: diagnosis and treatment
The clinical significance of renovascular arterial hypertension is determined by it is high prevalence as well as it is negative impact on prognosis. The most common causes of renovascular arterial hypertension are atherosclerotic stenosis of the renal arteries and fibromuscular dysplasia. Renovascular arterial hypertension is characterized by the development of blood pressure resistant to antihypertensive therapy with an unfavorable prognosis of worsening renal function and cardiovascular complications. Currently, the most available screening method in the diagnosis of renovascular arterial hypertension is duplex scanning of the renal arteries. Non-invasive diagnostic methods also include magnetic resonance and multispiral computed tomography with intravenous contrast. Contrast angiography remains “the golden standard” for diagnosing renovascular arterial hypertension and determining the indications for surgical treatment. Together with the use of diagnostic techniques such as measurement of translesion pressure gradient and fractional blood flow reserve, it allows to assess the functional significance of renal artery stenosis. Treatment of renovascular arterial hypertension is a complex process aimed at normalization of blood pressure, improvement of renal function, as well as mortality and cardiovascular risk reduction. To date, the feasibility of endovascular treatment remains an open question. More often the preference is given to conservative treatment. The indications for renal artery revascularization are less obvious, available clinical guidelines and results of large trials are controversial.
- Open Access
- 15 September 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (9) , 1018-1029
Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management
The diagnosis of resistant arterial hypertension allows us to single out a separate group of patients in whom it is necessary to use special diagnostic methods and approaches to treatment. Elimination of reversible factors leading to the development of resistant arterial hypertension, such as non-adherence to therapy, inappropriate therapy, secondary forms of arterial hypertension, leads to an improvement in the patient's prognosis. Most patients with resistant hypertension should be evaluated to rule out primary aldosteronism, renal artery stenosis, chronic kidney disease, and obstructive sleep apnea. The algorithm for examining patients, recommendations for lifestyle changes and a step-by-step therapy plan can improve blood pressure control. It is optative to use the most simplified treatment regimen and long-acting combined drugs. For a separate category of patients, it is advisable to perform radiofrequency denervation of the renal arteries.
- 15 September 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (9) , 1018-1029
Open AccessRussian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management
The diagnosis of resistant arterial hypertension allows us to single out a separate group of patients in whom it is necessary to use special diagnostic methods and approaches to treatment. Elimination of reversible factors leading to the development of resistant arterial hypertension, such as non-adherence to therapy, inappropriate therapy, secondary forms of arterial hypertension, leads to an improvement in the patient's prognosis. Most patients with resistant hypertension should be evaluated to rule out primary aldosteronism, renal artery stenosis, chronic kidney disease, and obstructive sleep apnea. The algorithm for examining patients, recommendations for lifestyle changes and a step-by-step therapy plan can improve blood pressure control. It is optative to use the most simplified treatment regimen and long-acting combined drugs. For a separate category of patients, it is advisable to perform radiofrequency denervation of the renal arteries.
- Open Access
- 1 January 2018
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 13 (2) , 22-25
The role of intervention methods of treatment of patients with resistant hypertension in contemporary cardiology
Medical article медицинская статья
- 1 January 2018
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 13 (2) , 22-25
Open AccessThe role of intervention methods of treatment of patients with resistant hypertension in contemporary cardiology
Medical article медицинская статья
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e173
[PP.10.13] ARTERIAL STIFFNESS AND ENDOTHELIAL FUNCTION IN PATIENTS WITH RESISTANT HYPERTENSION AFTER RENAL DENERVATION.
Objective: We study the effect of renal denervation (RDN) on arterial stiffness and arterial functional in patients with resistant hypertension 6 months after RDN. Design and method: We examined 21 patients, average 57 ± 10 years, before and 6 months after successful RDN. Initially mean blood pressure was 174 ± 12 mmHg. All patients continued take the original multicomponent antihypertensive therapy unchanged. Arterial stiffness was determined by volume sphygmograph (VaSera 1000) we assessed pulse wave velocity aortic (PWA) and cardio-ankle vascular index (CAVI); by applanation tonometry (SPhygmoCor) - carotid-femoral pulse wave velocity (PWVcf); by ultrasound method echo-TRACKING technology (Aloka Prosound α7) - stiffness index (B), modulus of elastic deformation (Ep), artery distensibility (AC). Endothelial function was evaluated by finger photoplethysmography during reactive hyperemia (Angioscan-01). We assessed the occlusion amplitude index for the determination of endothelial function in the microvasculature and the occlusion phase shift index for the determination of endothelial function in the arteries of muscular type. Six months after RDN 12 patients were classified as responders (mean systolic BP was reduced on 10 mmHg and more). Results: At baseline arterial stiffness was increased in 19 patients (90%) by PWVcf, in 13 (62%) by CAVI, PWA – 8 (38%), index B – 4 (19%), EP – 10 (48%), AC – 5 (24%). Baseline endothelial dysfunction was found in 17 patients (81%) by occlusion amplitude index, in 18 (85%) by occlusion phase shift index. 6 months after RDN in responders PWVcf decreased from 13,7 ± 3,6 to 12,5 ± 3,1 m/s (p < 0,01), CAVI from 7,08 ± 3,4 to 6,02 ± 3,8 (p < 0,05), AC increased from 0,71 ± 0,32 to 0,93 ± 0,5 mm2/Kpa (p < 0,05). Endothelial dysfunction had tendency to positive change: occlusion phase shift index increased from 1,28 ± 0,67 to 1,42 ± 0,32 (p = 0,07). All parameters of arterial stiffness and endothelial function had not positive changes in nonresponders. Conclusions: After 6 months of RDN we detected the improvement of some indicators of arterial stiffness and tendency to improve endothelial function in responders.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e173
[PP.10.13] ARTERIAL STIFFNESS AND ENDOTHELIAL FUNCTION IN PATIENTS WITH RESISTANT HYPERTENSION AFTER RENAL DENERVATION.
Objective: We study the effect of renal denervation (RDN) on arterial stiffness and arterial functional in patients with resistant hypertension 6 months after RDN. Design and method: We examined 21 patients, average 57 ± 10 years, before and 6 months after successful RDN. Initially mean blood pressure was 174 ± 12 mmHg. All patients continued take the original multicomponent antihypertensive therapy unchanged. Arterial stiffness was determined by volume sphygmograph (VaSera 1000) we assessed pulse wave velocity aortic (PWA) and cardio-ankle vascular index (CAVI); by applanation tonometry (SPhygmoCor) - carotid-femoral pulse wave velocity (PWVcf); by ultrasound method echo-TRACKING technology (Aloka Prosound α7) - stiffness index (B), modulus of elastic deformation (Ep), artery distensibility (AC). Endothelial function was evaluated by finger photoplethysmography during reactive hyperemia (Angioscan-01). We assessed the occlusion amplitude index for the determination of endothelial function in the microvasculature and the occlusion phase shift index for the determination of endothelial function in the arteries of muscular type. Six months after RDN 12 patients were classified as responders (mean systolic BP was reduced on 10 mmHg and more). Results: At baseline arterial stiffness was increased in 19 patients (90%) by PWVcf, in 13 (62%) by CAVI, PWA – 8 (38%), index B – 4 (19%), EP – 10 (48%), AC – 5 (24%). Baseline endothelial dysfunction was found in 17 patients (81%) by occlusion amplitude index, in 18 (85%) by occlusion phase shift index. 6 months after RDN in responders PWVcf decreased from 13,7 ± 3,6 to 12,5 ± 3,1 m/s (p < 0,01), CAVI from 7,08 ± 3,4 to 6,02 ± 3,8 (p < 0,05), AC increased from 0,71 ± 0,32 to 0,93 ± 0,5 mm2/Kpa (p < 0,05). Endothelial dysfunction had tendency to positive change: occlusion phase shift index increased from 1,28 ± 0,67 to 1,42 ± 0,32 (p = 0,07). All parameters of arterial stiffness and endothelial function had not positive changes in nonresponders. Conclusions: After 6 months of RDN we detected the improvement of some indicators of arterial stiffness and tendency to improve endothelial function in responders.